LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the appointment of Ronald Moy, M.D. to its Scientific Advisory Board. Dr. Moy, M.D., is a Board Certified Dermatologist and a diplomate of the American Board of Dermatology. He is a leader in the field of dermatology as a past President of the American Academy of Dermatology, Pacific Dermatologic Association and American Society for Dermatologic Surgery and as Vice President of the Skin Cancer Foundation.
Dr. Moy completed his dermatology residency training at UCLA and his Facial Cosmetic and Mohs Micrographic Surgery Fellowship training at the University of Pittsburgh Center for Health Services. He is a former professor at the David Geffen School of Medicine at UCLA, former Co-Chief of the UCLA division of Dermatology and former Chief of Dermatologic Surgery. He has served as president of the Los Angeles County Medical Association, Bay District and Editor-in-Chief of the Dermatologic Surgery Journal. Dr. Moy is also a published author of more than 200 articles on dermatologic surgery and treatments.
“We are excited to add Dr. Moy onto our Scientific Advisory Board to provide guidance on new products and enhanced offerings for our dermatologists. Dr. Moy’s experience with cutting edge technology and his foresight in the field of dermatology will be invaluable to DermTech as we further establish the company as the leader in non-invasive molecular testing for cancer and other skin conditions,” said Dr. Burkhard Jansen, DermTech’s CMO.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171206005193/en/
Sarah Dion, MBA
VP, Sales and Marketing
Source: DermTech, Inc.